Reviewing Rapport Therapeutics (RAPP) & Its Peers

Rapport Therapeutics (NASDAQ:RAPP) is one of 1,073 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Rapport Therapeutics to similar companies based on the strength of its valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Profitability

This table compares Rapport Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Rapport Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a breakdown of current ratings and target prices for Rapport Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	4	0	3.00
Rapport Therapeutics Competitors	8469	22350	50548	1359	2.54

Rapport Therapeutics presently has a consensus price target of $32.67, suggesting a potential upside of 240.28%. As a group, “Pharmaceutical preparations” companies have a potential upside of 236.04%. Given Rapport Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than its peers.

Earnings & Valuation

This table compares Rapport Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rapport Therapeutics	N/A	-$34.79 million	-0.69
Rapport Therapeutics Competitors	$9.89 billion	$136.37 million	-5.71

Rapport Therapeutics’ peers have higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rapport Therapeutics beats its peers on 7 of the 12 factors compared.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.